Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.
Virol J
; 18(1): 87, 2021 04 28.
Article
in English
| MEDLINE | ID: covidwho-1207602
ABSTRACT
The emergence and rapid spread of the B.1.1.7 lineage (VOC-202012/01) SARS-CoV-2 variant has aroused global concern. The N501Y substitution is the only mutation in the interface between the RBD of B.1.1.7 and ACE2, raising concerns that its recognition by neutralizing antibodies may be affected. Here, we assessed the neutralizing activity and binding affinity of a panel of 12 monoclonal antibodies against the wild type and N501Y mutant SARS-CoV-2 pseudovirus and RBD protein, respectively. We found that the neutralization activity and binding affinity of most detected antibodies (10 out of 12) were unaffected, although the N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23. These findings could be of value in the development of therapeutic antibodies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
Spike Glycoprotein, Coronavirus
/
SARS-CoV-2
/
Antibodies, Monoclonal
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Experimental Studies
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Virol J
Journal subject:
Virology
Year:
2021
Document Type:
Article
Affiliation country:
S12985-021-01554-8
Similar
MEDLINE
...
LILACS
LIS